Some products containing peptides are legally available as medicines, food supplements, dietary supplements or cosmetics. Others have the status of experimental substances, laboratory materials, prescription drugs or products whose advertising or sales methods may not meet the applicable requirements.
Therefore, the question „are peptides legal?” cannot be answered reliably with a single „yes” or „no” if all peptides are treated as one category.
To answer precisely, it is necessary to determine what exactly the product and active substance are, what its formulation is, in which country it is offered, for what purpose it is intended, and what activity the question concerns. The status of a peptide drug approved for sale under the healthcare system is a completely different matter than the status of an experimental substance advertised online, a cosmetic containing peptides, or a dietary supplement with peptide ingredients.
Another important distinction is also necessary. The marketing of a drug, the registration of a dietary supplement or cosmetic product, the possibility of importing a product and the possibility of using a specific substance in accordance with anti-doping regulations are separate issues. The presence of a product in one regulatory system does not automatically answer questions that belong to another system.
The Polish and EU registers of medicinal products, systems concerning food and cosmetics, the US drug databases, national regulatory authorities, and the regulations of the World Anti-Doping Agency all show well how different these legal frameworks can be.[1][2][3][4]
In this article, we explain how to check the regulatory status of products containing peptides using official sources and how to correctly interpret the information found. The sources used in preparing the material were verified on September 20, 2026. This article is for general information purposes only and does not constitute a determination that a specific purchase, import, possession, sale, delivery, administration, prescription, or use of the product is legal.
Why does there not exist one legal status for all peptides?
The word „peptide” describes a type of molecule. In itself, it does not determine the legal category of the product.
That is why searches like „are peptides legal?”, „are peptides legal in Poland?”, „are peptides legal in Europe?” or „can peptides be legally purchased online?” often lead to inaccurate answers.
Products containing peptides may be subject to completely different regulations.
The chemical description is not a legal category
Peptides are molecules composed of amino acid residues linked by peptide bonds.
This chemical definition does not specify whether the finished product is legally classified as a medicine, food, dietary supplement, cosmetic, laboratory material, or a product belonging to another category.
For example, the peptide component found in a moisturizing cream and the peptide active substance contained in a prescription drug pose completely different questions for the regulator.
Even two products labeled with the name of the same molecule do not necessarily have identical regulatory status.
They may differ in formulation, intended use, route of administration, labeling, declared action, manufacturer, responsible entity, or method of distribution.
Therefore, the regulatory classification should relate to the actual finished product and its intended use, and not just to the name of the common ingredient.
A good example is the EU regulation concerning cosmetic products. It defines cosmetics based on, among other things, the place of their use and the primary cosmetic purpose. At the same time, substances and mixtures intended for consumption, inhalation, injection or implantation into the human body are excluded from the definition of a cosmetic product.[5]
This means that the aesthetic purpose of the product alone does not automatically make the injection-ready product a cosmetic product.
Both the purpose and the method of administration are important.
The first question should be: „legally for what purpose?”
The statement that a particular peptide is „legal” is incomplete if it is not known what action it relates to.
One word can hide several different questions.
One person may want to know whether a product can be legally marketed in a given country. Another person may be interested in the possibility of importing it. Someone may be concerned about restrictions on possession, the ability to prescribe or dispense the product by a healthcare professional, its availability from a pharmacy, or whether an athlete can use it without violating anti-doping regulations.
These are not equivalent legal issues.
The analysis should therefore begin with a precise determination of the product and active substance, and if necessary also of the specific derivative or salt. The finished formulation, the anticipated route of administration, the country in which the activity takes place, and the type of activity itself must also be known, for example sales, import, delivery, professional use, or participation in sports subject to anti-doping regulations.
It is also worth noting the source of the regulatory information and the date of its verification.
These data allow the question to be defined correctly.
However, in themselves they do not constitute proof that a given activity is permitted.
The identity of the ingredient and the marketing of the product are two different matters
One of the most common mistakes is to assume that the marketing of one medicine containing a specific substance automatically means the marketing of all products containing the same ingredient.
Such a conclusion cannot be drawn.
The approval of a drug usually applies to a specific medicinal product.
Therefore, when checking the status, it is necessary to compare the actual product name, the responsible entity, the pharmaceutical form, the route of administration, the strength, if relevant, and the information identifying the authorization.
If the seller claims the approval of another product containing the same active substance, such entry does not automatically confirm the status of the product it offers.
The American database Drugs@FDA provides a good example of how information can be analyzed at the product level. It contains data on approved medicinal products covered by the database and related regulatory documents.[6]
This distinction is particularly important in online sales, where the name of a popular substance can be displayed very clearly, while the regulatory status of the actual product remains unclear.
The same principle applies to scientific research.
A publication found in PubMed or another scientific database confirms that a specific study has been described.
It is not an authorization to market the product.
It is not an import permit.
It does not constitute an authorization from the seller.
It also does not prove that every commercial product that uses the name of the investigated molecule is equivalent to the material used in the publication.
Scientific evidence and regulatory approval address two different questions.
The availability and popularity of a product do not confirm its legal status
The fact that a product can be easily purchased online does not mean that its advertising or sales are in compliance with applicable regulations.
The active purchase button simply means that the seller is accepting orders.
It is not evidence of regulatory approval.
Similarly, positive reviews may indicate that users have received or used the product, but they do not prove that the relevant authority has approved the product or that the transaction complies with local legal requirements.
The FDA described cases of GLP-1 products sold illegally online, including products marketed using terms associated with research use but also advertised for human use.[7]
This is a documented example showing why commercial availability alone should not be considered as confirmation of regulatory status.
However, this does not mean that every online seller of peptides or every product available online has the same status.
A similar distinction applies to delivery.
The fact that the shipment reached the customer does not prove that all requirements regarding import, customs law, medicinal products, pharmacy activities, consumer protection or other relevant regulations have been met.
The delivery of a shipment is a logistical event.
It is not a decision of the regulatory authority.
Therefore, a neutral assessment of the seller should separate information regarding customer service, shipping, product reviews, and marketing statements from independently verifiable regulatory information.
Medicines, cosmetics, dietary supplements and research materials
Products containing peptides can appear in several different regulatory systems.
Understanding these categories helps explain why a general statement about the legality of peptides is usually not sufficient.
Medicines require testing of a specific product
If a product is presented as a medicine, the most valuable regulatory evidence is the official entry regarding its marketing authorization, along with the current product information.
Depending on the country and the procedure used, the medicinal product characteristics, the patient information leaflet, assessment reports, regulatory decisions, labeling, or other documents may be available.
These documents relate to a specific preparation and specific conditions.
They should not be interpreted as approval of any possible use, combination of substances, route of administration, or commercial product using the same ingredient name.
A good example is semaglutide.
The EMA documentation regarding the product Rybelsus indicates semaglutide as the active substance of the oral tablet formulation and confirms its marketing authorization in the European Union. [8]
This is evidence regarding the product Rybelsus as a specific medicinal product authorised.
This does not mean that an independent retail product advertised as an „oral peptide,” „an alternative to semaglutide,” or a product described similarly is Rybelsus or takes over its regulatory status.
The permit is for the product described in the specific regulatory entry.
Cosmetics are subject to their own regulatory requirements
A cosmetic product does not become a medicine just because it contains a peptide.
At the same time, the presence of a peptide does not automatically mean that the product complies with the regulations regarding cosmetics.
The finished product must meet the appropriate definition of a cosmetic product and comply with applicable requirements.
In the European Union, these include issues regarding the responsible person, product safety assessment, product documentation, production, labeling, and other obligations regarding the finished cosmetic product.[5]
These requirements apply to the product as a whole.
Information about a single component is not sufficient to confirm the compliance of the entire formulation.
It is also worth correctly interpreting the EU Portal for the Notification of Cosmetic Products, or CPNP.
The CPNP is a notification system, not a public database of approved medicines.
The access is intended for specific professional users and regulatory authorities, including responsible persons, distributors, competent authorities and poison control centers.[3]
Therefore, information that a cosmetic product has been „registered in the CPNP” should not be interpreted as a claim that the product has received clinical approval similar to that of a medicinal product.
Notification and authorization of a medicinal product are two different regulatory concepts.
This also applies to cosmetics designed for specific areas of the skin. For example, in materials about peptides used around the eyes and peptides for sensitive and acne-prone skin we discuss cosmetic applications, but the mere presence of a peptide in such a product does not determine its legal status.
Dietary supplements are not medicines
The Main Sanitary Inspectorate explains that dietary supplements are food products intended to supplement the normal diet and are subject to the regulations of food law.[2]
Their marketing route differs from the procedure for approving medicinal products.
However, this does not mean that any substance can be legally sold as a dietary supplement.
The product must actually meet the requirements appropriate to its category.
The obligations may concern, among other things, composition, food hygiene, contamination, traceability, labeling, presentation methods, and other requirements of food law.
A separate issue is the declarations regarding the product's performance.
A scientific publication regarding a specific ingredient does not automatically mean that the seller can attribute any action to that ingredient in marketing materials.
GIS distinguishes between permitted nutritional and health claims and the presentation of food as a means of treating diseases.[2]
The regulatory status of a food product should therefore remain separate from claims regarding therapeutic efficacy.
The „research use only” label does not mean that it can be used in humans.
The term „research use only” describes the declared intended use of the product.
It is not a license to use it in humans.
It does not prove that the material has undergone the evaluation appropriate for the medicinal product.
It does not confirm its suitability for human use.
At the same time, the fact that legal laboratory tests are conducted on a given substance does not mean that every transaction involving research material is automatically prohibited.
The status depends on what the product actually is, how it is labeled, how it is advertised and delivered, what its declared purpose is, and what regulations apply in the given jurisdiction.
Therefore, you cannot judge a seller solely based on a single description on the vial or on the website.
The FDA’s description of products presented using research terminology, while at the same time being offered for human use, is a concrete example from the American market. [7]
However, it should not be transformed into a universal request concerning all research substances, all laboratory suppliers, and all countries.
The question of declared purpose is also important when interpreting information regarding the product. peptide therapy. The term used on the internet or in popular science publications does not in itself create a regulatory category or a permit to use a specific product.
A prescription drug and an FDA-approved product are not the same thing
In the United States, an important distinction applies to drugs prepared under the compounding process.
The FDA clearly indicates that such preparations are not FDA-approved products.
At the same time, the FDA recognizes that compounding can meet specific medical needs.[9]
Both of these facts must be considered together.
The lack of FDA approval alone does not answer every legal question regarding a specific product preparation under compounding.
The circumstances, the substance, the product being prepared, the appropriate regulations, and the specialists or institutions involved in this process are all important.
The mere designation of the product as „compounded” does not therefore prove that all legal requirements have been met.
At the same time, the term „not approved by the FDA” should not be automatically interpreted as a statement that any such product is illegal.
This distinction is particularly important when transferring American regulatory terminology to the Polish or European context.
The American system of compounding should not be automatically equated with Polish or EU legal solutions.
How to check the status of a peptide in Poland and the European Union?
When determining whether a specific product containing a peptide has a specific regulatory status in Poland or the EU, the official databases should be the starting point.
The search should be for the actual product, not for the entire category of peptides.
Start with the Polish Register of Medicinal Products
If the product is presented as a medicine used in Poland, one of the basic places to check is the Public Register of Medicinal Products, or RPL, which is available through official regulatory resources.
The URPL information indicates that the register covers medicinal products authorised under national procedures, mutual recognition, decentralised and centralised procedures, as well as parallel import authorisations.[1]
If the search system allows it, it is worth checking both the product name and the active ingredient.
Then the found entry must be compared with the product whose status we are trying to determine.
A similar name is not sufficient if the responsible entity, the pharmaceutical form, the route of administration, or other identifying data do not agree.
It is worth keeping the entry identifier and the date of the search.
Thanks to this, we receive a reproducible result of the regulatory check, instead of the general statement „I found it on the internet”.
The absence of a result should also be interpreted with equal caution.
If the product does not appear in the search engine, before formulating a broader request, it is worth checking the spelling, synonyms, the way the product is named, the scope of the register, and whether the relevant regulatory body is indeed the right one.
The lack of a product in one search is information about that specific search.
It does not automatically constitute a complete legal resolution.
Check both the European and national drug registries
The EMA publishes information about medicines that it assesses, but its website does not replace all national drug registration systems.
Therefore, the EMA also provides links to the registers maintained by EU and EEA countries. [10]
This is important because the product may have a national license, even if the user does not find a separate page for it in the EMA search engine.
The European Commission's EU register also contains information regarding centralized permits and other regulatory activities.[11]
However, it is necessary to check what exactly the found entry refers to.
A procedural entry, designation, information regarding the application or other regulatory record need not be equivalent to the granting of a permit to admit to trading.
Similarly, the situation should not be simplified to state that „approval in one European country means approval everywhere.”.
The territorial scope depends on the procedure and the specific regulatory decision.
Rybelsus is a simple example, because the EMA’s documentation clearly indicates its approval at the European Union level. [8]
For other products, it may be necessary to separately verify the national registers.
In the case of dietary supplements in Poland, check the sources of GIS
If the product is presented as a dietary supplement, the resources of the Main Sanitary Inspectorate will be a more appropriate source, rather than solely the records of medicinal products.
It is necessary to check the exact product and the entity responsible for it in the relevant official resources or notification systems.
The cropped screenshot presented by the seller is weaker evidence than the actual entry in the official system.
GIS also publishes information regarding changes to reported products, including situations where significant modifications may require a new notification. [12]
This shows why an old application should not be automatically treated as a description of a product that was later reformulated, renamed, or significantly modified.
The terminology used when describing the result is also important.
The report should be called a report.
It should not be presented as a counterpart to a marketing authorization for a medicinal product.
It also does not constitute proof that all the claimed effects have been clinically confirmed.[2]
Current EU law must be read in its proper context
EUR-Lex provides the European Union's legislation, including consolidated versions that take into account subsequent changes.
When analyzing a specific regulatory issue, it is necessary to check the correct version of the legal act and the date of its entry into force.
This is particularly important when the question concerns restrictions or conditions relating to a specific component, and not just the general legal framework.
In the case of cosmetics, the general definition and safety principles are different from the specific restrictions that may apply to certain ingredients.
Just reading the general regulation on cosmetics does not confirm that a specific finished formulation complies with all applicable regulations.[5]
The same principle applies to the bases of medicinal products.
The admission status must be distinguished from reimbursement, actual commercial availability, the product's presence in pharmacies, or the authenticity of a specific packaging.
The Register of Medicinal Products is not an up-to-date catalogue of pharmacies' stock levels.
Each regulatory source should be used to answer the question for which it was created.
What should a precise description of the regulatory status look like?
A good description should clearly indicate what has been verified.
For example, you could write:
„On the date indicated in the article, the official register contained an entry regarding this particular medicinal product, in a specific pharmaceutical form and belonging to the named responsible entity.”
Then it is necessary to explain what such a search did not confirm.
It may not verify the authenticity of the product offered by a specific seller.
It may not decide whether a specific cross-border import is allowed.
It may also not answer the question of whether an athlete can use a given substance in accordance with anti-doping regulations.
Such wording is much more informative than a general statement:
„Peptides are legal in Poland.”.
A narrower and more precise wording allows for the verification of the evidence and prevents the transformation of information about a single product into an unfounded assurance regarding the entire category.
How to check the status in the United States and other countries?
The same principle of analysis of a specific product applies outside of Poland and the European Union.
Each country has its own regulatory systems, terminology, and databases.
United States: Check the approval documentation, not the marketing statements
For many approved medicines used in humans in the United States, a good starting point is the Drugs@FDA database.
The FDA explains that it contains information regarding the majority of approved medicinal products covered by its historical scope and is updated daily.[6]
If a specific product cannot be found, the scope of this base must still be taken into account.
It is also important to distinguish between designations such as „FDA registered”, „FDA listed”, „manufactured in an FDA-registered facility” and „FDA approved”.
They do not mean the same thing.
The FDA explains in its consumer materials that the agency does not approve every type of product, facility, or regulatory action in the same way. [13]
Therefore, the declaration regarding registration or the FDA logo should be compared with the actual regulatory process, rather than being treated automatically as proof of product approval.
In the case of products regulated as biologics, the relevant FDA resources regarding biologics may also be important.
The goal remains the same: the actual product must be matched to the appropriate regulatory entry.
Import is a separate regulatory issue
The approval of a drug in one country does not automatically mean that it can be imported into another.
The American FDA guidelines regarding imports for personal use clearly show this difference.
A product can be approved abroad while not having approval in the United States. The FDA describes the limited circumstances considered under its policy regarding personal imports. [14]
These circumstances should not be interpreted as a general permission to import unapproved medicines.
The same principle applies internationally.
It is necessary to determine the target country and the specific activity.
The seller's declaration that „it is being sent to the whole world” is commercial information.
It is not an interpretation of customs or pharmaceutical regulations regarding medicines or imports in the recipient country.
Similarly, successful delivery does not confirm compliance with the regulations.
The shipment that reached the recipient confirms the delivery, not the regulatory approval.
Other countries require verification of their own national sources
In the United Kingdom, the official starting point are the MHRA resources regarding medicinal products and the relevant public assessment documents. [15]
In Canada, you can use the Drug Product Database maintained by Health Canada, which allows you to verify the identity of a product and its regulatory information.[16]
In Australia, relevant entries can be found in the Australian Register of Therapeutic Goods.[17]
For the other EU and EEA countries, the EMA catalogue leads to the relevant national registries. [10]
It is not necessary to treat all these databases as identical just because they contain regulatory data.
The terminology, product categories, legal consequences, and scope of information depend on the system of a given country.
Some countries also maintain separate databases for natural products, supplements, medical devices, cosmetics, and other categories.
Therefore, a simple search of the drug database does not necessarily exhaust all possible regulatory classifications.
What to do when the regulatory status is unclear?
If the result of the verification is ambiguous, the article should also leave that uncertainty visible.
If it has not been possible to confirm admission through verified official sources, the correct wording is:
„It has not been confirmed that admission has been granted in verified official sources.”.
This is much better than the automatic statement:
„This substance is illegal everywhere.”.
The next step should be to determine what information is missing.
Uncertainty may relate to the exact identity of the component, salt or derivative, the form of the product, the approval number, the jurisdiction, the intended use, or the type of the analyzed activity.
Only after the question has been properly defined can the appropriate authority or a suitably qualified local specialist address the specific situation.
This is particularly important in the case of cross-border distribution, imports, professional sales, and products whose classification may depend on the way they are presented or the declared purpose.
The general educational article does not replace the legal assessment of a specific transaction.
Anti-doping regulations constitute a separate issue
Regulatory approval and the possibility of using the substance in sports are two separate issues.
This distinction is particularly important in searches for peptides, because an athlete may understand the word „legal” as „allowed during competitions”.
These are not equivalent concepts.
The approval of a drug does not automatically mean that it is allowed in sports.
The drug may be legally approved for clinical use, while at the same time containing a substance prohibited by anti-doping regulations.
The WADA list of substances and methods prohibited for 2026 applies from January 1, 2026, and includes, among other things, certain categories of substances related to peptides.[4]
The specific substance and the wording of the relevant anti-doping category matter.
The mere presence of the word „peptide” in the product's name does not determine its status with WADA.
This does not mean that every peptide derived from food or every cosmetic containing peptides is prohibited.
Peptides derived from food, cosmetic ingredients, medications, peptide hormones, growth factors, mimetic agents, and other pharmacologically active substances cannot be grouped together in a single category simply because the term “peptide” appears in their names.
This topic is particularly relevant when it comes to content related to peptides for muscle growth and bodybuilding and peptides and testosterone, Where scientific, regulatory and anti-doping questions should remain clearly separated.
The named examples do not constitute the entire anti-doping rule.
Just searching for the exact name of the substance on the WADA list may not be enough.
The list includes both specific examples and broader categories.
Category S0 concerns certain unapproved pharmacological substances, whereas S2 covers peptide hormones, growth factors, related substances, and mimetic agents. [4]
Therefore, you need to read the entire category, and not limit yourself to finding the name of the product.
WADA also recommends in its online materials that a full category be analyzed and that contact be made with the appropriate anti-doping organization if a given substance cannot be identified unequivocally. [18]
Therefore, the statement „I did not find a name on the list” does not automatically mean „WADA allows it”.
A broader description of the category may be relevant.
The recipe is not automatically off-limits for therapeutic purposes
The Therapeutic Use Exemption, or TUE, is part of the anti-doping system.
It is not simply another name for a prescription.
WADA explains that TUE applications are reviewed by the appropriate anti-doping organization, for example the national anti-doping organization or the international federation, in accordance with the relevant rules. [19]
Medical documentation or a prescription may form part of the supporting materials for such a request.
However, the prescription itself is not automatically a TUE.
The level of the athlete's competition, proper organization, specific substance, medical situation, and applicable regulations are all important factors.
Therefore, it is necessary to separate the three questions.
The first concerns whether the product is legally placed on the market or supplied.
The second concerns its recognized medical use.
The third concerns whether the anti-doping regulations allow the athlete to use them or require a TUE.
A positive answer to one of these questions does not automatically answer the others.
Frequently asked questions about the legality and regulatory status of peptides
Does the availability of the peptide on the internet mean that it is legal?
No. The online offer confirms that the seller is offering the product, but does not prove that the product or transaction meets the requirements of the destination country. The FDA has documented cases of products sold online in violation of regulations, including preparations presented using misleading terminology regarding research use.[7] Customer reviews, the ability to make payments, and successful delivery do not replace checking the status of a specific product in the relevant regulatory sources.
Does the product's approval in one country apply everywhere?
Not automatically. The regulatory permit has a specific territorial scope. A centralized EU permit may apply across the EU, as shown by the example of the product Rybelsus. [8] In turn, US import regulations show that allowing a product to be imported does not automatically create its approval in the United States. [14] One must always check the actual regulatory decision and its scope.
Are all peptides prescription drugs?
No. Products containing peptides may fall under different regulatory categories, and the chemical composition itself does not determine their classification. The GIS distinguishes dietary supplements and medicinal products, whereas EU regulations define cosmetics separately. [2] [5] Before determining a prescription status, the finished product, its intended use, formulation, presentation method, and the appropriate jurisdiction must be known.
Does the approval of a drug containing a given substance mean that every seller of that substance is operating legally?
No. The authorization applies to a specific medicinal product, not to every material or vendor that uses the name of its active ingredient. The Drugs@FDA database clearly demonstrates the product-specific nature of the approval documentation. [6] A seller offering an independent product cannot automatically assign it the regulatory status of another drug simply because the active ingredient name is the same.
Does the submission of a dietary supplement to the GIS mean its approval as a drug?
No. The notification regarding a dietary supplement belongs to the system of food law, whereas the authorization of a medicinal product is a separate regulatory process. The GIS explains the important differences between dietary supplements and medicinal products. [2] Therefore, reports should not be presented as approval of therapeutic efficacy or evidence that the product has undergone a clinical evaluation typical of medicines.
Is the CPNP a public database of approved peptide cosmetics?
No. CPNP is a portal for the notification of cosmetics by specific market participants and authorities, rather than a public database of approved products similar to a drug registry.[3] Notification serves a regulatory function different from that of product approval and in itself does not confirm clinical efficacy or all aspects of product compliance.
Can an injection product be considered a cosmetic product in the EU just because it has an aesthetic purpose?
Not in the sense of the definition contained in the EU regulation concerning cosmetics. Substances and mixtures intended for injection into the human body are excluded from the definition of a cosmetic product. [5] The aesthetic purpose itself does not change the boundary resulting from the route of administration. The specific product requires proper regulatory classification.
Does the lack of a product on the EMA website mean that it is not approved in Poland?
No. The EMA website does not cover all medicinal products authorised at national level, therefore the EMA also refers to the Member State registries. [10] In the case of Poland, therefore, you should also check the RPL and the documentation for the specific product. A lack of result in one EMA search is not sufficient to fully determine the product status.
Does „FDA registered” mean „FDA approved”?
No. Registration, listing, and approval are separate regulatory concepts. The FDA’s consumer materials explain that the mere requirement for a facility to register or list a specific product category does not automatically mean that the product has been approved by the FDA. [13] Therefore, before accepting an approval declaration, it is necessary to check the exact entry and the appropriate regulatory pathway.
Does the publication in PubMed confirm the legal introduction of the product on the market?
No. Publication indexed in PubMed means that a specific scientific study has been published. Access to the market is governed by appropriate legal and regulatory procedures. The FDA’s description of the evaluation of drugs shows a separate process related to the approval of products. [20] A scientific publication may provide information about the substance under study, but it does not replace a marketing authorization.
Does the foreign prescription automatically allow for import?
Such a universal rule cannot be formulated. The FDA guidelines for personal imports distinguish between foreign product approval and individual circumstances and the requirements in the United States.[14] Other countries apply their own regulations. Therefore, prescriptions should not be considered as a global permit for import. The destination country and the specific circumstances must be checked.
Is a legally available peptide automatically allowed in sports?
No. Regulations regarding medicinal products and anti-doping regulations are two separate systems. The WADA list also includes substances that may be present in legally used medications. [4] Therefore, sporting status requires a separate analysis according to current anti-doping rules. Legal clinical use does not automatically mean that an athlete can use substances without restrictions.
Is the prescription the same as the TUE?
No. The TUE is a formal exception operating within the anti-doping system. WADA describes the procedure for submitting applications through the appropriate anti-doping organization and for their evaluation according to specific criteria. [19] The prescription and medical documentation may be part of the application, but the prescription itself does not automatically constitute a TUE.
Does the absence of a peptide from the WADA list mean that it is allowed?
This cannot be assumed. WADA recommends considering entire categories of prohibited substances and consulting with the appropriate anti-doping organization if a specific substance cannot be unequivocally identified. [18] Regulations regarding related substances, mimetic substances, or unapproved pharmacological substances may be relevant. The absence of an exact name on the list is therefore not an automatic confirmation that the substance is permitted.
What should a reliable description of the regulatory status of a peptide look like?
It should indicate the exact product, the appropriate active substance, the country where the analysis was conducted, the official source and the date of the test. Official resources, such as the Polish RPL or the British MHRA systems, allow the information to be linked to specific products. [1] [15] If there remains uncertainty, it should be clearly indicated so that the verified information regarding a single product is not mistakenly extended to the entire category of peptides.
Restrictions on information regarding the legality and regulatory status of peptides
The regulatory status can be more complex than a single search in the database suggests.
The first limitation is jurisdiction. A product may have a specific status in Poland, another in the United States, and another in another country. A statement without information about the country is therefore often incomplete.
The second limitation is the specific nature of the product. Allowing one ready-made medicinal product does not mean allowing all preparations containing the same substance.
The third category is regulatory. Medicines, cosmetics, food, dietary supplements, prescription drugs, and laboratory materials may be subject to different systems.
The fourth limitation is the type of activity. The placing on the market, sale, import, possession, prescription, dispensing, and use of substances in regulated sports can give rise to different legal questions.
The fifth area is the scope of databases. The absence of a result in one official system does not necessarily mean that the corresponding entry does not exist elsewhere. The relationship between the EMA database and the national EU registers illustrates well why the scope of the source is important. [10]
The sixth limitation is time. Regulatory decisions, permits, regulations, anti-doping lists, and official guidelines can change. Therefore, the article regarding regulations should indicate the date of verification of sources.
The seventh problem is the authenticity of the product. Finding a license for the original drug does not prove that the product offered by a particular retailer is authentic or that the retailer has the right to deliver it.
The ninth limitation is the cross-border complexity. A product that is legally placed on the market in one country may be subject to different requirements during import or sale in another country.
Finally, regulatory status should not be equated with scientific evidence. A publication may describe research on a substance without establishing a right to its sale, and regulatory approval does not mean approval of every marketing claim regarding a given ingredient.
Therefore, precise and context-specific conclusions are usually more reliable than broad statements like „peptides are legal” or „peptides are illegal”.
It is also worth remembering that the legal status and safety of a product are separate issues. The approval for marketing does not mean the absence of adverse effects; the lack of approval is not in itself an indication of the substance's toxicity. We explain these issues in more detail in the article on side effects and safety of peptides.
Summary
There is no one universal answer to the question „are peptides legal?”.
Peptides are a broad chemical category, whereas regulatory systems primarily concern specific products, applications, routes of administration, declarations, activities, and jurisdictions.
Some products containing peptides are approved as medicines. Others are found in cosmetics or foods subject to different regulations. Some substances remain experimental, and some products advertised online may not meet the requirements regarding how they are presented or delivered.
Therefore, the correct question is not simply:
„Is this peptide legal?”
A more useful question is:
„What is the regulatory status of this particular product, for this particular activity, in this country and at this time?”
In the case of a product marketed in Poland as a medicine, RPL and the relevant EU resources can provide information regarding the specific authorization. [1] [10] In the case of dietary supplements, GIS resources are essential. [2] Cosmetics in the EU operate under their own regulatory and notification system. [3] [5] In the United States, the status of specific medications can be checked, among other things, at Drugs@FDA and other relevant FDA resources. [6]
Cross-border imports require separate analysis. A product approved abroad does not automatically receive approval in the destination country, and successful delivery of the shipment does not prove compliance with all legal requirements.[14]
Sport creates another independent regulatory layer. Legally available drugs may contain a substance prohibited by anti-doping regulations. Therefore, the current WADA list and the rules regarding the TUE must be checked separately. [4] [19]
The most reliable description of the regulatory status should indicate the exact product, active substance, formulation, jurisdiction, activity under investigation, official source, and date of verification.
It should also clearly indicate what has not been determined.
The approval of a product containing a specific ingredient does not mean that all preparations containing this ingredient are allowed.
A scientific publication is not a license to market the product.
Availability on the internet does not mean regulatory approval.
The „research use only” label does not constitute permission to use it in humans.
The notification of a dietary supplement is not an approval of a drug.
Notifying the CPNP is not an authorization of the medicinal product.
Registration with the FDA does not always mean approval by the FDA.
The recipe is not automatically a TUE.
And the absence of an exact name for the substance on the WADA list does not automatically mean that it is allowed.
Maintaining these distinctions allows for a much more accurate description of the status of products than attempting to assign one legal status to an entire category of peptides.
Disclaimer
The article is of general educational nature and serves to provide information regarding regulations. It does not constitute legal, medical or customs advice, instructions regarding the prescription of medicines, import permits, confirmation of compliance with anti-doping regulations, or a determination that a specific product, purchase, possession, shipment, sale, method of delivery, prescription, administration or use is legal.
Regulatory classifications and applicable requirements may depend on the specific product, active substance, formulation, intended use, labeling, route of administration, seller or supplier, jurisdiction, type of activity, and current regulations. Regulatory entries and official guidelines may also change over time.
Persons verifying a specific product should use the current official register or information from the competent authority responsible for the jurisdiction and type of activity. Questions regarding commercial distribution, import, professional delivery of products, border classification of the product, or individual legal situation may require consultation with a suitably qualified specialist.
In performance sports, the approval of a medicinal product and the legality of its supply should not be interpreted as confirmation of compliance with anti-doping regulations. Athletes should use the current anti-doping rules and procedures of the relevant anti-doping organization to determine whether a substance is prohibited or whether an exclusion is required for therapeutic purposes.
References
- Office for the Registration of Medicinal Products, Medical Devices and Biocidal Products. (2015, December 16). Register of medicinal products. Register of medicinal products
- The Main Sanitary Inspectorate. (2025, September 30). Dietary supplements vs. medicinal products [Food supplements versus medicinal products]. Dietary supplements vs. medicinal products [Food supplements versus medicinal products]
- European Commission. (n.d.). Cosmetic product notification portal. Retrieved September 20, 2026, from Cosmetic product notification portal
- World Anti-Doping Agency. (2025). World Anti-Doping Code: International standard—Prohibited list 2026. World Anti-Doping Code: International standard—Prohibited list 2026
- European Parliament & Council of the European Union. (2009). Regulation (EC) No 1223/2009 on cosmetic products (consolidated version of May 18, 2026). Regulation (EC) No 1223/2009 on cosmetic products (consolidated version of May 18, 2026)
- U.S. Food and Drug Administration. (n.d.). About Drugs@FDA. Retrieved September 20, 2026, from About Drugs@FDA
- U.S. Food and Drug Administration. (n.d.). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved September 20, 2026, from FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- European Medicines Agency. (n.d.). Rybelsus: European public assessment report. Retrieved September 20, 2026, from Rybelsus: European public assessment report
- U.S. Food and Drug Administration. (n.d.). Understanding the risks of compounded drugs. Retrieved September 20, 2026, from Understanding the risks of compounded drugs
- European Medicines Agency. (n.d.). National registers of authorised medicines. Retrieved September 20, 2026, from National registers of authorised medicines
- European Commission. (n.d.). Union Register of medicinal products. Retrieved September 20, 2026, from Union Register of medicinal products
- The Main Sanitary Inspectorate. (2024, December 18). Information regarding making changes to a notification for first-market introduction [Changes to a first-market notification]. Information regarding making changes to a notification for first-market introduction [Changes to a first-market notification]
- U.S. Food and Drug Administration. (n.d.). Is it really ‘FDA approved’?. Retrieved September 20, 2026, from Is it really ‘FDA approved’?
- U.S. Food and Drug Administration. (n.d.). Personal importation. Retrieved September 20, 2026, from Personal importation
- Medicines and Healthcare products Regulatory Agency. (2026, August 10). Find product information about medicines. Find product information about medicines
- Health Canada. (2015, June 18). Drug Product Database: Access the database. Drug Product Database: Access the database
- Therapeutic Goods Administration. (n.d.). Australian Register of Therapeutic Goods (ARTG). Retrieved September 20, 2026, from Australian Register of Therapeutic Goods (ARTG)
- World Anti-Doping Agency. (n.d.). The Prohibited List. Retrieved September 20, 2026, from The Prohibited List
- World Anti-Doping Agency. (n.d.). Therapeutic use exemptions (TUEs). Retrieved September 20, 2026, from Therapeutic use exemptions (TUEs)
- U.S. Food and Drug Administration. (n.d.). The FDA’s drug review process: Ensuring drugs are safe and effective. Retrieved September 20, 2026, from The FDA’s drug review process: Ensuring drugs are safe and effective